Plan Development for Giving Teclistamab in the Outpatient Setting

This is a pilot study to develop an outpatient-based process for the administration of teclistamab for for relapsed/refractory multiple myeloma patients and to evaluate the burden on caregivers of patients receiving outpatient administration of teclistamab.

Trial Details

NCT ID
NCT06251076
Phase
PHASE4
Sponsor
University Health Network, Toronto
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Teclistamab
  • Tocilizumab
Locations (sample)
  • Toronto, Ontario, Canada|43.65333,-79.38389

Key Eligibility Criteria

  • Eligible for teclistamab treatment as per Health Canada approved indication:
  • Age 18 and greater
  • Relapsed or refractory multiple myeloma
  • Received at least 3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →